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Abstract
Background: The dynamics of CD4+ T cell reconstitution and changes in immune activation and inflammation in
HIV-1  disease  following  initiation  of  antiretroviral  therapy  (ART)  are  incompletely  defined  and  their  underlying
mechanisms poorly understood.
Methods:  Thirty-nine  treatment-naïve  patients  were  treated  with  raltegravir,  tenofovir  DF  and  emtricitabine.
Immunologic and inflammatory indices were examined in persons with sustained virologic control during 48 weeks of
therapy.
Results: Initiation of ART increased CD4+ T cell numbers and decreased activation and cell cycle entry among
CD4+ and CD8+ T cell subsets, and attenuated markers of coagulation (D-dimer levels) and inflammation (IL-6 and
TNFr1). These indices decayed at different rates and almost all remained elevated above levels measured in HIV-
seronegatives through 48 weeks of viral control. Greater first and second phase CD4+ T cell restoration was related
to lower T cell activation and cell cycling at baseline, to their decay with treatment, and to baseline levels of selected
inflammatory indices, but less so to their changes on therapy.
Conclusions: ART initiation results in dynamic changes in viral replication, T cell restoration, and indices of immune
activation, inflammation, and coagulation. These findings suggest that determinants of T cell activation/cycling and
inflammation/coagulation may have distinguishable impact on immune homeostasis.
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HIV-1  infection  is  characterized  by  T  cell  activation,
inflammation,  and  hyper-coagulation,  yet,  effects  of
antiretroviral therapy (ART) on dynamics of these indices and
correlates  of  CD4+  T  cell  reconstitution  are  incompletely
understood.  Depletion  of  CD4+  T  cells  is  driven  in  part  by
HIV-1 replication [1]; however, increasing evidence implicates
immune  activation  as  an  important  correlate,  and  possible
determinant  of  CD4+T  cell  depletion  and  disease  outcome
[2–4].  Potential  drivers  of  activation  include:  activation  by
components  of  HIV-1  [5–7],  by  copathogens  such  as
cytomegalovirus  [8],  by  Toll-like  receptor  (TLR)  ligands
translocated from the damaged gut [9–12], or by homeostatic
responses to lymphocytopenia [13,14]. Exposure of peripheral
blood  mononuclear  cells  to  TLR  ligands  activates  T  cells  in
vitro [6,15] and certain TLR ligands can drive memory CD4+ T
cells  into  cell  cycle  and  death  [15].  As  ART  results  in
decreased  plasma  levels  of  HIV-1  and  both  plasma
inflammatory markers and cellular markers of T cell activation
[9,10,16–18], we hypothesized that a detailed assessment of
the decay dynamics of these indices after ART initiation would
provide insight into the determinants of immune restoration in
treated HIV-1 infection; and, by inference, into the determinants
of  cellular  turnover,  inflammation,  and  immune  deficiency  in
HIV-1 disease.
Materials and Methods
Ethics Statement
This study was approved by institutional review boards at all
participating  sites:  Brigham  and  Women's  Hospital  Clinical
Research Site (CRS), Johns Hopkins Adult AIDS CRS, UCSD,
AVRC CRS, University of Rochester ACTG CRS, AIDS Care
CRS, Washington University CRS, The Ohio State University
AIDS CRS, MetroHealth CRS, Northwestern University CRS,
The  Miriam  Hospital  ACTG  CRS,  Vanderbilt  Therapeutics
CRS,  IHV  Baltimore  Treatment  CRS,  University  of  Colorado
Hospital CRS, Houston AIDS Research Team CRS, and the
Harlem  ACTG  CRS.  This  trial  is  registered  with
Clinicaltrials.gov # NCT00660972.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Design
A5248 was a prospective, open-label, multicenter, pilot study
performed in the United States of America between June 2008
and April 2010. HIV-1 infected ART-naïve patients with plasma
HIV-1 RNA levels >10,000 and <300,000 copies/mL and any
CD4+  T  cell  counts  enrolled  after  providing  written  informed
consent.  Subjects  were  ineligible  if  screening  genotype
identified major nucleoside reverse transcriptase inhibitor, non-
nucleoside reverse transcriptase inhibitor, or protease inhibitor
resistance mutations. HIV-1 RNA and CD4+ T cell count were
measured at pre-entry and entry visits and the geometric and
arithmetic means were used, respectively, to establish baseline
values. Participants were treated with raltegravir (RAL, 400 mg
twice daily) and emtricitabine/tenofovir disproxil fumarate (FTC/
TDF, 200mg/300mg once daily). Data obtained after virologic
failure (VF) or clinical rebound (CR) on or before week 48 were
excluded  from  analyses.  Virologic  failure  was  defined  as  a
confirmed plasma HIV-1 RNA level ≥1000 copies/mL at or after
16 weeks and before 24 weeks, or ≥200 copies/mL at or after
24 weeks. Clinical rebound was defined as confirmed plasma
HIV-1 RNA >0.3 log10 c/mL above the previous measurement
[19] .
Sample collection
Blood samples were collected at pre-entry, entry, day 2, day
7, and weeks 2, 4, 8, 24, and 48. Absolute CD4+ and CD8+ T
cell  counts  were  obtained  in  real-time.  Peripheral  blood
mononuclear  cell  (PBMC)  samples  were  cryopreserved  until
analyzed  in  batch.  Whole  blood  samples  collected  in  EDTA-
containing tubes were centrifuged for 10 minutes at 495 x g
and  plasma  was  frozen  at  -80°C  until  thawed  once  and
analyzed in batch.
Plasma was assayed for HIV-1 RNA using the AMPLICOR
HIV-1  Monitor  version  1.5,  UltraSensitive  (US)  protocol  (≤50
copies/mL;  Roche  Molecular  Systems,  Branchburg,  New
Jersey, USA)
Flow cytometry
CD4+ and CD8+ T cells were identified by size, granularity,
and  staining  with  antibodies  to  CD4  or  CD8.  The  following
antibody-fluorochrome  conjugates  (and  appropriate  isotype
controls) were used: anti-CD4 (Pacific Blue, Becton Dickinson
(BD)  Pharmingen,  San  Diego,  CA),  anti-CD8  (Peridinin-
chlorophyll-protein Complex, PerCP), Franklin Lakes, NJ), anti-
CD45RA  (allophycocyanin,  APC,BD  Pharmingen),  anti-Ki-67
(phycoerythrin, PE, BD Pharmingen), anti HLA-DR (fluorescein
isothiocyanate,  FITC  (BD  Biosciences),  anti  CD38  (PE,  BD
Biosciences),  and  anti-CCR7  (PE-Cy7,BD  Pharmingen).  To
assure  accuracy  when  analyzing  lymphocyte  subsets,  only
quadrants with more than 300 cells were reported. For analysis
of  intracellular  Ki-67,  cells  were  incubated  with  FACS
Permeabilizing  Solution  (BD  Biosciences)  for  15  minutes,
washed then stained with anti-Ki-67 antibody or with an isotype
control antibody for 45 minutes in the dark.  Cells were then
washed and fixed with 1% formaldehyde, and analyzed using
an LSR II flow cytometer (BD).
Plasma assays
Levels  of  soluble  CD14  (sCD14),  tumor  necrosis  factor
receptor  type  1  (TNFr1),  and  interleukin-6  (IL-6)  were
measured  using  the  Quantikine  ELISA  kits  (all  from  R&D
Systems Minneapolis MN). Levels of D-dimers were measured
using the Asserachrom D-DI immunoassay (Diagnostica Stago,
Asnieres France).
Plasma  levels  of  LPS  were  quantified  using  the  Limulus
Amebocyte  Lysate  (LAL)  assay  (QCL-1000,  Lonza,
Walkersville, MD) according to the manufacturer’s protocol as
previously described [20]
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To compare immunologic indices to those found in health,
cryopreserved  PBMC  and  plasma  samples  from  21  healthy,
HIV-uninfected control subjects were thawed and then cellular
and plasma markers of immune activation were measured as
above  by  the  same  laboratory.  The  inflammatory  and
coagulation indices data were reported previously [21]. The 21
healthy control donors included 11 men; their ages ranged from
23-60 years.
Statistical Methods
P-values  were  two-sided  and  not  adjusted  for  multiple
comparisons.  For  this  exploratory  analysis,  nominal
significance was attached to p-values of <5%. Wilcoxon signed
rank tests were used to evaluate significance of changes from
baseline.  Wilcoxon  rank  sum  tests  were  used  to  evaluate
differences  between  findings  in  patients  and  controls.
Spearman  (rank-based)  correlations  were  used  to  evaluate
associations between outcomes
Results
Thirty-nine subjects met criteria for immunologic evaluation.
In subjects who exhibited VF or CR at any time on or before
week 48, data are excluded after the earliest such event. Two
subjects did not have viable PBMC available, but had plasma
samples for analysis. Thus, sample sizes ranged from 37 (39
for  soluble  markers)  at  baseline  to  27  at  week  48.  Baseline
characteristics for the 39 study patients and 21 healthy controls
are  shown  in  Table  1.  With  administration  of  ART,  plasma
HIV-1  RNA  levels  fell  rapidly  and  decreased  significantly  by
day  2  (not  shown).  By  day  28,  median  levels  were  <  50
copies/mL.
With  initiation  of  ART,  circulating  CD4+  T  cell  numbers
typically increase biphasically, with a rapid first phase increase
attributed to cellular redistribution from lymphoid tissues, and a
second phase increase that has been attributed to homeostatic
T cell expansion [13,14]. Here, we observed rapid first phase
CD4+  T  cell  restoration  reaching  inflection  around  week  4,
followed  by  a  slower  second  phase  restoration  (Figure  1A),
although  CD4+T-cell  counts  through  week  48  did  not  reach
levels seen in uninfected controls. By week 48, however, 16 of
31  (52%)  subjects  had  CD4+  T-cell  counts  exceeding  500
cells/uL. Circulating CD8+ T lymphocyte numbers also typically
rise  during  first  phase  restoration,  then  may  increase  or
diminish  [16,22].  Circulating  CD8+  T  cell  numbers  rose
transiently by day 2; but, by week 4, were no longer different
from  baseline  levels  and  remained  higher  than  levels  seen
among uninfected controls (Figure 1B).
Naïve  CD4+  T  cells  represent  the  broad  repertoire  of
potential responses to neoantigens, while central memory (CM)
T cells reflect anamnestic potential upon antigen re-exposure.
In clinical studies, naïve CD4+ T cell numbers are predictive of
total  CD4+  T  cell  restoration  [23],  whereas  CM  CD4+  T  cell
turnover has been linked to disease progression in non-human
primate models [24]. Naïve and CM CD4+ T cells increased
significantly  from  baseline  by  days  2  and  7,  respectively,
(p<0.001  and  p=0.001,  Figures  1C  and  1D),  yet  neither
population  reached  levels  seen  in  healthy  controls  even  by
week 48 (p<0.001 for both at week 48.)
Expression of CD38 and HLA-DR has been directly linked to
T  cell  depletion,  and  has  been  inversely  related  to  T  cell
reconstitution on ART [2,3]. Here, proportions of CD38+/DR+
CD4+ and CD8+ T cells decreased significantly from baseline
by 2 days and 7 days after initiation of therapy (p= 0.05 and
0.015, respectively, Figures 2A and 2B). At no time over 48
weeks  did  proportions  of  activated  CD4+  and  CD8+  T  cells
normalize to levels seen in healthy controls (p<0.001 for both).
Though  these  phenotypic  indices  of  activation  predict
outcome  in  untreated  HIV-1  infection,  it  is  likely  that  T  cell
turnover  is  more  closely  linked  to  death  of  CD4+  T  cells
[24–26]. Here, the frequency of cycling CD4+ T cells did not fall
significantly  until  week  8  (p<0.001,  Figure  2C),  but  the
increased  proportions  of  cycling  (Ki67+)  CD8+  T  cells  fell
rapidly  from  baseline  by  day  7  (p=0.028,  Figure  2D)  .  Both
remained  elevated  throughout  the  study  when  compared  to
levels in healthy controls (p<0.001 for both). The proportions of
naïve  and  CM  CD4+  T  cells  expressing  Ki67  also  did  not
decrease significantly until week 8 (p<0.001, Figure 2E, 2F),
and  their  frequencies  did  not  reach  the  proportions  seen  in
healthy controls at any time.
Untreated  HIV-1  infection  is  characterized  by  inflammation
and coagulation [27–29]. Plasma levels of IL-6 and D-dimers
(products of fibrinolysis) predict mortality in HIV-1 infection [28]
and  pretreatment  plasma  levels  of  the  TNFr1  and  IL-6  also
predicted AIDS events and death in treated patients [30,31].
Initiation of ART decreased plasma levels of IL-6, TNFr1, and
D-dimer,  by  week  4  (p=0.002,  p=0.031,  and  p=0.028,
respectively;  Figure  3A-3C).  Levels  of  TNFr1  and  D-dimers
Table 1. Baseline demographics and clinical characteristics
of patients enrolled in A5248 and uninfected controls.
Characteristic
HIV-1 Infected
Patients(N=39)
HIV-1 Uninfected
Controls
    (N=21)
Gender Male= 35 (90%) Males = 11 (52%)
  Female= 4 (10%) Females = 10 (48%)
Age (years) Median = 44 Median= 37
  Range = 23-58 Range = 23-60
Race/Ethnicity    
White Non-Hispanic 18 (46%) 16 (76%)
Black Non-Hispanic 11 (28%) 2 (9%)
Hispanic (Regardless of
Race)
7 (18%) 1 (5%)
Asian   1 (5%)
More than 1 Race 2 (5%)  
Unknown/Missing 1 (3%) 1 (5%)
Plasma HIV-1 RNA (c/mL) Median = 37, 490 Not applicable
  Range= 6,644 - 619, 795  
CD4+ T cell count
(cells/µL)
Median = 259 Median = 907
  Range= 150-599 Range= 544-1957
doi: 10.1371/journal.pone.0083514.t001
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among healthy controls.
We next examined the decay in plasma levels of bacterial
LPS and of the soluble LPS coreceptor, sCD14. At weeks 24
and 48, LPS levels were significantly lower than baseline (p<
0.05  for  both)  yet  failed  to  reach  levels  seen  in  uninfected
controls (both p<0.001, Figure 3D). Levels of sCD14 decreased
rapidly and were significantly lower than baseline by day 2 and
continued to fall until they reached a plateau between week 8
and 24; and at weeks 24 and 48 remained higher than levels in
uninfected controls (p<0.05 for both; Figure 3E).
We explored several mechanistic hypotheses by examining
correlations  among  baseline  indices  (Table  2).  We
hypothesized that CD8+ T cell cycling was potentially driven by
viremia (as we had earlier found that CD8+ T cell cycling was
not increased in patients with durable control of viremia [21])
and that CD4+ T cell cycling was likely driven by both viremia
and microbial translocation, as CD4+ T cell cycling could be
induced in vitro by both bacterial and viral TLR ligands [15].
Figure 1.  Initiation of antiretroviral therapy (ART) results in an increase in the number of CD4+T cells and a decrease in the
number of CD8+ T cells.  Absolute CD4+ and CD8+ T cell counts were obtained in real time on fresh whole blood samples.
Lymphocytes were identified by flow cytometry based on size and granularity; T cell subsets were identified by positive expression
of CD4 or CD8. The numbers of circulating A) CD4+ and B) CD8+ T cells within this HIV-1 infected patient population changed
significantly from baseline by day 2 (p<0.001 and p<0.002, respectively), but did not reach levels seen in healthy controls within 48
weeks  of  ART  treatment.  C)  naïve  (CD45RA+  CCR7+)  and  D)  central  memory  (CM,  CD45RA-CCR7+)  CD4+  T  cell  numbers
increased significantly by day 2 (p<0.001) and day 7 (p=0.001) respectively. Symbols used in the figure:
N = Normal controls (in blue).
0 = Baseline.
D = Day (The two tick-marks between “0” and “D14” are Day 2 and Day 7).
W = Week.
* = Change from baseline significantly different from 0 (Wilcoxon signed rank p ≤0.05) .
x = Significant difference from the normal controls (Wilcoxon rank sum p ≤0.05).
- Horizontal bars represent 25th (Q1), 50th (Median), and 75th percentiles.
… Dotted line (in red) connects the medians over time.
doi: 10.1371/journal.pone.0083514.g001
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PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83514Figure  2.    Proportions  of  activated  (CD38+HLA-DR+)  and  cycling  (Ki67+)  CD4+  and  CD8+  T  cells  decreased  following
initiation of ART.  Among both A) CD4+ and B) CD8+ T cell populations, initiation of raltegravir plus emtricitabine/tenofovir resulted
in a significant decrease from baseline in the proportion of activated cells by 2 days and 7 days (p= 0.05 and 0.015, respectively).
By week 48, the proportions of activated CD4+ and CD8+ T cells in these patients did not approach the proportions measured in
healthy controls. Also among both C) CD4+ and D) CD8+ T cell populations, initiation of ART significantly decreased the proportions
of Ki67+ cells by week 8 and by day 7 respectively (p<0.001 and p=0.028). E) Naïve CD4+ T cells (CD4+,CD45RA+, CCR7+) and
F) CM CD4+ T cells (CD4+,CD45RA-, CCR7+) that express Ki67 were significantly reduced from baseline by week 8 (p=0.005 and
p=0.001, respectively). In all four T cell subsets, proportions of Ki67+ cells did not approach the proportions seen in healthy controls
by week 48 of the study. Symbols used in the figure:
N = Normal controls (in blue).
0 = Baseline.
D = Day (The two tick-marks between “0” and “D14” are Day 2 and Day 7).
W = Week.
* = Change from baseline significantly different from 0 (Wilcoxon signed rank p ≤0.05) .
x = Significant difference from the normal controls (Wilcoxon rank sum p ≤0.05).
- Horizontal bars represent 25th (Q1), 50th (Median), and 75th percentiles.
… Dotted line (in red) connects the medians over time.
doi: 10.1371/journal.pone.0083514.g002
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PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e83514Figure 3.  Markers of inflammation and coagulation are reduced following initiation of ART.  Plasma samples were thawed
and levels of A) interleukin-6 (IL-6) B) tumor necrosis factor receptor type 1 (TNFr1) C) D-dimers D) Lipopolysaccharide (LPS) and
E) CD14 (sCD14) were measured. Initiation of ART resulted in significant decreases from baseline in plasma levels of IL-6 and
TNFr1 by week 4 (p=0.002 and p=0.038) D-dimer levels were significantly reduced by day 7 (p=0.031). Levels of sCD14 were
significantly reduced by day 2 following initiation of therapy (p<0.001). LPS levels were significantly reduced from baseline 24 weeks
after initiation of ART (p<0.001). None of these markers, except for IL-6, consistently reached the levels seen in healthy controls by
the end of the study. Symbols used in the figure:
N = Normal controls (in blue).
0 = Baseline.
D = Day (The two tick-marks between “0” and “D14” are Day 2 and Day 7).
W = Week.
* = Change from baseline significantly different from 0 (Wilcoxon signed rank p ≤0.05) .
x = Significant difference from the normal controls (Wilcoxon rank sum p ≤0.05).
- Horizontal bars represent 25th (Q1), 50th (Median), and 75th percentiles.
… Dotted line (in red) connects the medians over time.
doi: 10.1371/journal.pone.0083514.g003
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not find a significant association between viremia and CD8+ T
cell cycling or between CD4+ T cell cycling and levels of either
LPS  or  sCD14.  We  did  find  a  positive  association  between
baseline levels of sCD14 and several other markers, including
plasma IL-6, D-dimers, TNFr1, and the proportion of both CD4+
and  CD8+  T  cells  that  expressed  HLA-DR  and  CD38,
suggesting  that  sCD14,  as  a  marker  of  monocyte  activation/
microbial  translocation,  is  related  to  indices  of  inflammation,
coagulation and T cell activation in HIV-1 disease (Table 2).
Soluble  CD14  levels  at  baseline  were  inversely  related  to
baseline numbers of absolute, naïve, and CM CD4+ T cells, but
not  to  CD8+  T  cell  counts;  consistent  with  the  concept  that
immune  activation/inflammation  may  drive  or  be  a
consequence of CD4+ T cell loss.
We next examined the relationship between baseline indices
of activation and inflammation and the magnitude of CD4+ T
cell restoration. Among the baseline indices examined, levels
of  CD4+  T  cell  cycling  (r=  -0.39,  p=0.03),  proportions  of
activated CD38+ HLA-DR+ CD4+ T cells (r= -0.41, p=0.029),
and  levels  of  TNFr1(r=  -0.43,  p=0.013),  were  correlated
negatively with the 48 week increase in total CD4+ T cells. The
48  week  increase  in  naïve  CD4+  T  cells  was  correlated
negatively  with  the  baseline  proportions  of  cycling  CD4+  (r=
-0.45, p=0.016), cycling CM CD4+ T cells (r= -0.40, p=0.033),
and cycling CD8+ T cells (r= -0.39, p=0.043), and with baseline
sCD14  (r=  -0.42,  p=0.028).  No  baseline  indices  significantly
correlated with CM CD4+ T cell increases (not shown). As had
been shown previously [23], baseline naïve CD4+ T cell counts
predicted  total  CD4+  T  cell  increases  at  week  48(r=0.47,
p=0.008), as did baseline central memory CD4+ T cell count
(r=0.41, p=0.025).
Since  different  mechanisms  are  proposed  for  the  biphasic
CD4+ T cell restoration, we next asked if any baseline indices
of activation are related to either first phase (redistribution) or
second  phase  (expansion)  increases.  None  of  the  baseline
activation,  cycling,  or  inflammatory  markers,  was  correlated
with first phase total CD4+ T cell increases (from week 0 to
week  4,  Table  3).  When  we  examined  separately  the
restoration of phenotypically naïve CD4+ T cells and CM CD4+
T cells, significant correlations were uncovered. Baseline CD4+
(but not CD8+) T cell activation correlated inversely with the
magnitude  of  first  phase  naïve  CD4+  T  cell  restoration  (r=
-0.66,  p<0.001),  as  did  the  baseline  proportions  of  cycling
CD4+,  naïve  CD4+  and  CM  CD4+  T  cells  (r=  -0.44,  -0.42,
-0.46,  p=  0.007,  0.009,  and  0.004,  respectively).  Among
inflammatory indices, baseline levels of sCD14 were inversely
correlated  with  first  phase  naïve  CD4+  T  cell  restoration  (r=
-0.43, p=0.008). First phase restoration of CM cells correlated
significantly only with baseline levels of IL-6 (r= -0.35, p=0.03).
Baseline  levels  of  IL-6  did  not  predict  first  phase  or  second
phase  restoration  of  any  other  maturation  subset.  Second
phase (week 8-48) increases in CD4+ T cells and their naïve
and  CM  subsets,  were  negatively  correlated  with  baseline
proportions of activated CD4+ T cells (r= -0.42, -0.4, and -0.52,
p=  0.009,  0.014,  and  0.001,  respectively),  and  with  their
proportions  of  cycling  (r=  -0.38,  -0.39,  and  -0.47,  p=  0.021,
0.016, and 0.003). Total and CM CD4+ T cell second phase
increases  correlate  negatively  with  cycling  CM  CD4+  T  cells
(r=-0.37 and -0.48, p= 0.022 and 0.003), and negatively with
baseline  levels  of  TNFr1  (r=  -0.36  and  -0.34,  p=  0.03  and
0.041). Second phase naïve CD4+ T cell restoration correlated
inversely  with  baseline  naïve  CD4+  T  cell  cycling  (r=  -0.33,
p=0.05);  but  for  restoration  of  total  and  CM  CD4+  T  cells,
correlations with baseline naïve CD4+ T cell cycling were not
significant. The magnitude of baseline HIV-1 viremia was not
associated with any indices of CD4+ T cell restoration.
We next asked whether decay of immune and inflammatory
indices in the first phase (week 0-4) and second phase (week
8-48)  were  correlated  with  first  (Table  4)  or  second  phase
(Table  5)  CD4+  T  cell  restoration.  Interestingly,  the  only
significant relationships for first phase cellular restoration were
seen  for  naïve  CD4+  T  cells,  wherein  smaller  decreases  in
cycling of all CD4+ T cell subsets were associated with greater
CD4+  T  cell  restoration  (Table  4).  Smaller  second  phase
decreases  in  CD4+  T  cell  cycling  and  CD4+  T  cell  subset
cycling also significantly correlated with greater second phase
naïve CD4+ T cell restoration and also tended to correlate with
greater restoration of total CD4+ and CM CD4+ T cells (Table
5).  While  this  may  be  the  consequence  of  lower  baseline
cycling,  these  relationships  at  baseline  and  with  therapy
suggest  that  in  this  setting,  cycling  of  CD4+  T  cells  is  less
homeostatic than driven by other mechanisms.
Discussion
The intensive immunologic monitoring in this study allowed
fine characterization of treatment related changes in immune
and  inflammatory  indices  and  an  exploration  of  their
relationships  to  immune  restoration.  CD8+  T  cell  numbers
increased during the first two weeks, stabilized by week 4, and
then fell, such that circulating CD8+ T cell numbers were not
different from baseline after 4 weeks. While circulating CD4+ T
cell numbers are characteristically low in HIV+ patients, CD8+
T  cell  numbers  are  expanded  and  in  this  study  remained
elevated (compared to numbers in healthy controls) throughout
48 weeks.. Typically, HIV-1 reactivity among circulating CD8+
T cells falls with suppression of HIV-1 replication [32,33]. Are
these expanded cells reactive with other microbial pathogens
(e.g. cytomegalovirus)? Or do they represent long lived cells
resistant to cell death? The determinants and significance of
this persistent expansion remain to be determined, but does
not appear to be a consequence of “blind T cell homeostasis”
as a result of CD4+ lymphopenia, as CD8+ T cell expansion is
even  more  demonstrable  among  ART  treated  persons  who
normalize CD4+ T cell numbers than among immune failures
who do not [21]. In this study the bulk of CD8+ T cell expansion
reflected  increases  in  the  numbers  of  effector  memory  and
terminally differentiated effector memory cells (not shown).
Confirming  previous  reports  [34],  we  observed  biphasic
restoration of CD4+ T cells and their maturation subsets. The
determinants  of  this  biphasic  cellular  restoration  are
incompletely understood. Earlier work has suggested that the
rapid first phase of cellular restoration is most compatible with
a redistribution of lymphocytes sequestered in inflamed lymph
nodes  [13,14]  and  the  second  phase  is  related  to  increased
Activation Decay with ART
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e83514T
a
b
l
e
 
2
.
 
C
o
r
r
e
l
a
t
i
o
n
 
c
o
e
f
f
i
c
i
e
n
t
s
 
(
r
)
 
f
o
r
 
a
s
s
o
c
i
a
t
i
o
n
s
 
a
m
o
n
g
 
b
a
s
e
l
i
n
e
 
i
m
m
u
n
o
l
o
g
i
c
 
i
n
d
i
c
e
s
.
B
a
s
e
l
i
n
e
 
o
u
t
c
o
m
e
s
C
D
4
 
C
o
u
n
t
C
D
8
 
C
o
u
n
t
C
e
n
t
r
a
l
M
e
m
o
r
y
 
C
D
4
C
o
u
n
t
N
a
ï
v
e
 
C
D
4
C
o
u
n
t
N
a
ï
v
e
 
C
D
8
C
o
u
n
t
%
 
T
o
t
a
l
K
i
6
7
+
C
D
4
+
%
 
T
o
t
a
l
K
i
6
7
+
C
D
8
+
%
 
K
i
6
7
+
N
a
ï
v
e
 
C
D
4
%
 
K
i
6
7
+
C
e
n
t
r
a
l
M
e
m
o
r
y
 
C
D
4
%
 
C
D
3
8
+
/
H
L
A
-
D
R
+
C
D
4
%
 
C
D
3
8
+
/
H
L
A
-
D
R
+
C
D
8
I
L
-
6
T
N
F
r
1
D
-
d
i
m
e
r
L
P
S
s
C
D
1
4
H
I
V
-
1
R
N
A
C
D
4
 
C
o
u
n
t
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
D
8
 
C
o
u
n
t
0
.
3
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
e
n
t
r
a
l
 
M
e
m
o
r
y
C
D
4
 
C
o
u
n
t
N
A
0
.
3
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
a
ï
v
e
 
C
D
4
 
C
o
u
n
t
N
A
0
.
4
1
*
0
.
5
6
*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
a
ï
v
e
 
C
D
8
 
C
o
u
n
t
0
.
3
0
N
A
0
.
3
4
*
0
.
5
3
*
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
T
o
t
a
l
-
0
.
3
0
-
0
.
0
2
-
0
.
2
8
-
0
.
4
6
*
-
0
.
3
7
*
 
 
 
 
 
 
 
 
 
 
 
 
K
i
6
7
+
 
C
D
4
+
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
T
o
t
a
l
-
0
.
1
9
0
.
0
3
-
0
.
0
7
-
0
.
4
4
*
-
0
.
3
9
*
0
.
8
6
*
 
 
 
 
 
 
 
 
 
 
 
K
i
6
7
+
 
C
D
8
+
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
K
i
6
7
+
-
0
.
2
6
-
0
.
0
8
-
0
.
1
8
-
0
.
4
4
*
-
0
.
3
2
0
.
8
8
*
0
.
8
2
*
 
 
 
 
 
 
 
 
 
 
N
a
ï
v
e
 
C
D
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
K
i
6
7
+
 
C
e
n
t
r
a
l
M
e
m
o
r
y
 
C
D
4
-
0
.
4
4
*
-
0
.
0
5
-
0
.
3
7
*
-
0
.
4
6
*
-
0
.
3
4
*
0
.
9
3
*
0
.
7
8
*
0
.
8
4
*
 
 
 
 
 
 
 
 
 
%
 
C
D
3
8
+
/
-
0
.
6
0
*
-
0
.
2
3
-
0
.
7
2
*
-
0
.
6
8
*
-
0
.
5
6
*
0
.
5
2
*
0
.
3
8
*
0
.
3
8
*
0
.
5
2
*
 
 
 
 
 
 
 
 
H
L
A
-
D
R
+
 
C
D
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
C
D
3
8
+
/
-
0
.
2
0
0
.
2
0
-
0
.
2
2
-
0
.
0
9
-
0
.
3
1
0
.
0
1
0
.
0
6
-
0
.
1
1
0
.
0
3
0
.
4
0
*
 
 
 
 
 
 
 
H
L
A
-
D
R
+
 
C
D
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
L
-
6
0
.
0
5
0
.
0
9
0
.
0
9
0
.
1
5
0
.
0
8
-
0
.
0
2
0
.
0
6
-
0
.
0
8
-
0
.
0
5
-
0
.
1
0
-
0
.
0
4
 
 
 
 
 
 
T
N
F
r
1
-
0
.
2
0
-
0
.
1
6
-
0
.
2
6
-
0
.
2
3
-
0
.
2
6
0
.
0
7
0
.
1
3
-
0
.
1
2
0
.
0
0
2
0
.
3
3
*
0
.
2
6
0
.
4
7
*
 
 
 
 
 
D
-
d
i
m
e
r
-
0
.
3
0
0
.
0
4
-
0
.
0
4
-
0
.
2
2
-
0
.
2
0
0
.
1
8
0
.
2
9
0
.
1
0
0
.
2
5
0
.
0
7
0
.
0
7
0
.
4
1
*
0
.
3
3
*
 
 
 
 
L
P
S
0
.
0
5
0
.
3
2
0
.
0
8
0
.
1
4
0
.
2
1
0
.
1
2
0
.
2
2
0
.
0
8
0
.
0
8
-
0
.
1
4
-
0
.
0
2
0
.
0
0
5
0
.
1
5
0
.
2
2
 
 
 
s
C
D
1
4
-
0
.
3
5
*
-
0
.
0
0
6
-
0
.
3
3
*
-
0
.
4
1
*
-
0
.
2
8
0
.
2
4
0
.
2
6
0
.
0
9
0
.
1
6
0
.
5
2
*
0
.
4
7
*
0
.
3
8
*
0
.
6
1
*
0
.
3
8
*
0
.
1
3
 
 
H
I
V
-
1
 
R
N
A
-
0
.
1
2
-
0
.
1
6
-
0
.
1
5
-
0
.
1
9
-
0
.
1
5
0
.
0
1
0
.
0
1
0
.
0
7
0
.
0
0
5
0
.
0
7
-
0
.
1
0
0
.
2
6
0
.
2
3
0
.
1
4
-
0
.
2
6
0
.
0
5
 
(
S
p
e
a
r
m
a
n
)
 
c
o
r
r
e
l
a
t
i
o
n
 
c
o
e
f
f
i
c
i
e
n
t
s
 
a
r
e
 
i
n
 
b
o
l
d
 
a
n
d
 
l
a
b
e
l
e
d
 
w
i
t
h
 
a
n
 
a
s
t
e
r
i
s
k
 
(
*
)
 
w
h
e
n
 
t
h
e
 
a
s
s
o
c
i
a
t
i
o
n
s
 
a
r
e
 
s
i
g
n
i
f
i
c
a
n
t
 
(
p
-
v
a
l
u
e
 
<
 
0
.
0
5
)
.
d
o
i
:
 
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
8
3
5
1
4
.
t
0
0
2
Activation Decay with ART
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e83514Table  3.  Correlation  coefficients  (r)  for  associations  between  CD4  count  restoration  and  baseline  immunologic/virologic
markers.
SUBJECT-SPECIFIC ESTIMATE Baseline Markers
 
% CD38+/
HLA-DR+ CD4
% CD38+/
HLA-DR+
CD8
% Total
Ki67+ CD4+
% Ki67+
Central
Memory CD4
% Ki67+
Naive CD4+ IL-6 TNFr1 LPS sCD14
HIV-1
RNA
First-phase restoration CD4 T-cell count -0.002 0.19 0.08 0.12 0.05 -0.09 0.15 0.24 0.08 0.16
  Naïve CD4 count -0.66* -0.14 -0.44* -0.46* -0.42* 0.06 -0.19 0.14 -0.43* -0.09
 
Central Memory
CD4 count
0.14 0.19 0.01 0.05 0.06 -0.35* -0.01 0.02 -0.14 0.05
(BL to week 4)                      
Second-phase
restoration (week 8 to
week 48) 
CD4 T-cell count -0.42* -0.02 -0.38* -0.37* -0.23 -0.06 -0.36* 0.17 -0.29 0.02
  Naïve CD4 count -0.40* 0.02 -0.39* -0.30 -0.33* 0.02 -0.25 0.17 -0.32 -0.06
 
Central Memory
CD4 count
-0.52* -0.06 -0.47* -0.48* -0.28 -0.09 -0.34* 0.17 -0.30 -0.05
(Spearman) correlation coefficients are in bold and labeled with an asterisk (*) when the associations are significant (p-value < 0.05).
doi: 10.1371/journal.pone.0083514.t003
Table 4. Correlation coefficients (r) for associations between first-phase cell restoration and immunologic decay.
SUBJECT-SPECIFIC ESTIMATE First-phase Immunologic Decay (BL to Week 4)
 
% CD38+/HLA-
DR+ CD4
% CD38+/HLA-
DR+ CD8
% Total Ki67+
CD4+
% Ki67+ Central
Memory CD4
% Ki67+ Naive
CD4+ IL-6 TNFr1 LPS sCD14
First-phase
restoration (BL to
week 4) 
CD4 T-cell count 0.29 0.07 -0.02 0.01 0.003 -0.09 -0.23 -0.19 0.003
  Naïve CD4 count 0.11 -0.24 0.57* 0.65* 0.46* -0.005 0.02 0.09 0.32
 
Central Memory
CD4 count
-0.04 -0.20 -0.08 -0.03 -0.69 0.19 -0.09 0.11 0.06
(Spearman) correlation coefficients are in bold and labeled with an asterisk (*) when the associations are significant (p-value < 0.05).
doi: 10.1371/journal.pone.0083514.t004
Table 5. Correlation coefficients (r) for associations between second-phase cell restoration and immunologic decay.
SUBJECT-SPECIFIC ESTIMATE Second-phase Immunologic Decay (Week 8 to Week 48)
 
% CD38+/HLA-DR
+ CD4
% CD38+/HLA-DR
+ CD8 % TotalKi67+ CD4+
% Ki67+ Central
Memory CD4
% Ki67+ Naive
CD4+ IL-6 TNFr1 LPS sCD14
Second-phase
restoration (week 8
to week 48)
CD4 T-cell count 0.10 0.17 0.40* 0.29 0.31 0.19 0.10 0.23 0.32
  Naïve CD4 count 0.27 0.18 0.41* 0.34* 0.38* -0.01 0.22 0.29 0.15
 
Central Memory
CD4 count
0.24 0.29 0.39* 0.39* 0.28 0.22 0.21 0.16 0.40*
(Spearman) correlation coefficients are in bold and labeled with an asterisk (*) when the associations are significant (p-value < 0.05).
doi: 10.1371/journal.pone.0083514.t005
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expression in any CD4+ T cell population during this time, our
data suggest that cellular increases are not a consequence of
greater proliferation; but could plausibly be related to less cell
death as suggested by DeMascio [35]. In fact, greater CD4+ T
cell  restoration,  in  both  the  first  and  second  phases,  was
related to lower levels of CD4+ T cell activation and cycling at
baseline, and to decreases in these indices following initiation
of therapy. Earlier works found an inverse relationship between
CD4+  T  cell  counts  and  their  cycling  [35–37],  yet  increased
cycling  in  HIV  infection  could  reflect  either  homeostatic
responses to cytopenia, or may drive cell losses as these cells
die, or both. The data generated in this prospective clinical trial
of antiretroviral therapy are compatible with a role for CD4+ T
cell  cycling  in  pathogenesis  of  cell  losses.  In  this  regard,
baseline  levels  of  inflammatory  markers,  TNFr1,  IL-6,  and
sCD14, were negatively associated with increases in CD4+T
cell populations. We have recently found that the inflammatory
cytokines IL-6 and IL-1β drive both CD4 T cell turnover and
diminish CD4 T cell responses to the homeostatic cytokine IL-7
[38].
A  growing  body  of  evidence  links  immune  activation  and
inflammation  to  the  pathogenesis  of  immune  deficiency
[2,3,9,10,21] and to morbid outcomes of HIV-1 infection [28].
Here,  both  CD4+  and  CD8+  T  cells  remained  activated
throughout  the  course  of  this  study,  and  although  the
proportions  of  activated  T  cells  diminished,  they  remained
significantly  higher  than  among  healthy  controls.  In  fact,  in
other studies, activation of CD4+ and CD8+ T cells can persist
despite  years  of  virologic  control  [3,21],  and  we  found
persistent activation despite declining viremia below 50 copies
of  HIV-1  RNA/mL  as  measured  by  single  copy  assay  [19].
While the determinants of persistent activation in this setting
remain  incompletely  understood,  the  data  here  implicate
activation  and  inflammation  also  in  the  pathogenesis  of
immune deficiency.
A unique feature of our study was the frequent measurement
of immune activation markers soon after the initiation of ART.
Notably,  several  markers  of  immune  activation  and
inflammation began to normalize within days of starting ART. 
We found no significant relationship between the early changes
in  plasma  HIV-1  RNA  level  and  changes  in  activation/
inflammation  markers  or  cellular  restoration.  This  may  result
from the exclusion from the trial of subjects with low levels of
viral  replication  (<10,000  copies/mL)  and  the  relatively  small
size of the study.
And  despite  rapid  reduction  in  plasma  HIV-1  RNA  levels,
systemic  levels  of  LPS  and  its  soluble  coreceptor,  sCD14
remained elevated for the duration of the study. These results
suggest  that  factors  other  than  ongoing  viral  replication  may
provide  the  stimulus  to  persistent  immune  activation  in  HIV-
infected  patients.  These  observations  are  consistent  with
earlier observations that in most instances the damage to gut
immunity does not completely resolve with ART [39]. It is also
clear that sCD14 decays much more rapidly from plasma than
does LPS, consistent with the concept that factors other than
LPS also may drive plasma levels of this coreceptor [40].
Recent works have linked the morbidities and mortalities of
treated  HIV-1  infection  to  increased  inflammatory  and
coagulation indices [28,31,41]. Here, levels of the inflammatory
cytokine  IL-6,  the  soluble  cytokine  receptor  TNFr1,  the  LPS
coreceptor  sCD14,  and  D-dimer  markers  of  fibrinolysis,  fell
during ART; yet, despite one year of effective therapy, plasma
levels of TNFr1, sCD14, and D-dimers, remained higher than
among healthy controls.
By  examining  the  relationships  between  activation/
inflammation indices and both first phase and second phase
cellular  restoration,  we  have  found  that  both  first  phase  and
second  phase  naïve  CD4+  T  cell  restoration  was  linked
inversely to the magnitude of first and second phase decreases
in CD4+ T cell cycling and activation. Though less robust, the
second phase recovery of all CD4+ T cells and of CM CD4+ T
cells was also linked inversely to the decrease in CD4+ T cell
cycling.  These  data  suggest  that  while  T  cell  activation  and
inflammatory/coagulation  markers  may  be  linked  to  immune
deficiency and HIV-related morbidity and mortality, the factors
that drive them may be complex and distinguishable in terms of
their  relationship  to  immune  restoration.  Our  data  are  more
compatible  with  a  model  wherein  activation  and  cycling  are
driving  pathogenesis  rather  than  being  reflective  of
homeostasis.  While  the  processes  that  drive  immune
deficiency and inflammation are triggered by HIV-1 infection,
suppression of HIV-1 replication with effective ART does not
fully correct the residual immune dysregulation that even after
a year of therapy is linked to the newer morbidities of HIV-1
infection.
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